Screening for autoimmune markers is unnecessary during follow-up of adults with autoimmune thrombocytopenic purpura and no autoimmune markers at onset

Thrombosis and Haemostasis

Volumn 83, Issue 1, 2000, Pages 42-45

  Vantelon, J M ^a   Godeau, B ^a,b   Andre C ^c   Bierling, P ^a,c  

^a Lab d'Immunologie Plaquettaire   (France)

^b HÔpital Henri Mondor   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

Antinuclear antibody; Autoantibody; Autoimmune thrombocytopenic purpura; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; HUMAN IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RHEUMATOID FACTOR; STEROID;

ADOLESCENT; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; FEMALE; FOLLOW UP; GRAVES DISEASE; HASHIMOTO DISEASE; HEMOLYTIC ANEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; SCREENING TEST; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIC PURPURA;

EID: 0033964441     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613754     Document Type: Article

References (16)

1. Boumpas DT, Austin HA, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concept. Part I: renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995; 122: 940-50.
2. Mestanza-Peralta M, Ariza-Ariza R, Cardiel MH, Alcocer-Varela J. Thrombocytopenic purpura as initial manifestation of systemic lupus erythematosus. J Rheumatol 1997; 24: 867-70.
3. Morley KD, Bernstein RM, Bunn CC, Gharavi AE, Fortin MT, Chipping PM, Hughes GRV. Thrombocytopenia and anti-Ro. Lancet 1981; ii: 940.
4. Anderson MJ, Peebles CL, McMillan R, Curd JG. Fluorescent antinuclear antibodies and anti-SS-A/Ro in patients with immune thrombocytopenia subsequently developing systemic lupus erythematosus. Ann Intern Med 1985; 103: 548-51.
5. Perez HD, Katler E, Embury S. Idiopathic thrombocytopenic purpura with high-titer, speckled pattern antinuclear antibodies: possible marker for systemic lupus erythematosus. Arthritis Rheum 1985; 28: 596-7.
6. Panzer S, Penner E, Graninger W, Schulz E, Smolen JS. Antinuclear antibodies in patients with chronic idiopathic autoimmune thrombocytopenia followed 2-30 years. Am J Hematol 1989; 32: 100-3.
7. Kurata Y, Miyagawa S, Kosugi S et al. High-titer antinuclear antibodies, anti-SS-A/Ro antibodies and antinuclear RNP antibodies in patients with idiopathic thrombocytopenic purpura. Thromb Haemost 1994; 71: 184-7.
8. George JN, El-Harake MA, Easkob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1994; 331: 1207-11.
9. George JN, Woolf SH, Raskob GE et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 2-40.
10. Tan E, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
11. Piette JC. Diagnosis and classification criteria for the antiphospholipiod/ cofactors syndrome: a "mission impossible"? Lupus 1996; 5: 354-63.
12. Picozzi VJ, Roeske WR, Creger WP. Fate of therapy failures in adult idiopathic thrombocytopenic purpura. Am J Med 1980; 69: 690-4.
13. Vantelon JM, Godeau B, Bierling P. Modalités évolutives et réponses aux traitements du purpura thrombopénique auto-immun de l'adulte: à propos d'une série monocentrique de 122 cas. Rev Med Interne 1997; 18 (Suppl 2): 114.
14. Bompas DT, Barez S, Klippel J, Balow JE. Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 1990; 112: 674-7.
15. Stasi R, Stipa E, Masi M et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98: 436-42.
16. Finazzi G, Brancaccio V, Moia M et al. Natural history and risk factor for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from Italian registry. Am J Med 1996; 100: 530-6.